EL7.AI
StocksMedium•16 November 2026•
1 min read

EMA Committee Backs Biosimilar Insulins in Blow to Novo Nordisk

Key Facts

1The EMA's expert committee recommended approval for two biosimilar insulins, increasing competition for Novo Nordisk.
2The committee once again rejected a drug originally developed by the Danish company Orphazyme.

The European Medicines Agency's (EMA) expert committee recommended the approval of two biosimilar insulin products to increase competition against Novo Nordisk. MedWatch reported that these recommendations aim to expand treatment options within the European market, while the committee also issued a warning regarding Eli Lilly's Mounjaro. Additionally, the committee once again rejected a drug originally developed by the Danish company Orphazyme.

Novo Nordisk shares, trading under the ticker NVO, closed at $41.63 on November 13, 2026. The stock saw a trading range between a low of $40.64 and a high of $41.8 during that session. These regulatory developments occur as the company faces mounting pressure from biosimilars targeting its established insulin market share.

Open on chart